Editorial Commentary: Mycoplasma genitalium and Declining Treatment Efficacy of Azithromycin 1 g: What Can We Do?

ly systematic review and meta-analysis of azithromycin 1 g treatment studies of Mycoplasma genitalium ,b y Lau et al

[1]  P. Muir,et al.  2015 UK National Guideline on the management of non-gonococcal urethritis , 2016, International journal of STD & AIDS.

[2]  J. Hocking,et al.  The Efficacy of Azithromycin for the Treatment of Genital Mycoplasma genitalium: A Systematic Review and Meta-analysis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  F. Garrett,et al.  P09.03 Treatment of mycoplasma genitalium with azithromycin 1 g is less efficacious and associated with induction of macrolide resistance compared to a 5-day regimen , 2015 .

[4]  P. Muir,et al.  O28 Treatment of mycoplasma genitalium with azithromycin 1 g is less efficacious and associated with induction of macrolide resistance compared to a 5 day regimen , 2015, Sexually Transmitted Infections.

[5]  J. Hocking,et al.  The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. , 2015, The Journal of antimicrobial chemotherapy.

[6]  S. Garland,et al.  Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  K. Workowski,et al.  Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. McNulty,et al.  Positivity at test of cure following first-line treatment for genital Mycoplasma genitalium: follow-up of a clinical cohort , 2014, Sexually Transmitted Infections.

[9]  R. Guy,et al.  Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  C. Hoebe,et al.  High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women , 2014, BMC Infectious Diseases.

[11]  L. Manhart.  Diagnostic and resistance testing for Mycoplasma genitalium: what will it take? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  J. Jensen,et al.  Direct Detection of Macrolide Resistance in Mycoplasma genitalium Isolates from Clinical Specimens from France by Use of Real-Time PCR and Melting Curve Analysis , 2014, Journal of Clinical Microbiology.

[13]  E. Adams,et al.  Time to manage Mycoplasma genitalium as an STI: but not with azithromycin 1 g! , 2014, Current opinion in infectious diseases.

[14]  C. Carder,et al.  A cross-sectional study of Mycoplasma genitalium infection and correlates in women undergoing population-based screening or clinic-based testing for Chlamydia infection in London , 2014, BMJ Open.

[15]  G. Gilbert,et al.  Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance , 2013, International journal of STD & AIDS.

[16]  J. Jensen,et al.  Treatment of Mycoplasma genitalium. Observations from a Swedish STD Clinic , 2013, PloS one.

[17]  S. Garland,et al.  Transmission and Selection of Macrolide Resistant Mycoplasma genitalium Infections Detected by Rapid High Resolution Melt Analysis , 2012, PloS one.

[18]  P. Horner.  Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy , 2012, Sexually Transmitted Infections.

[19]  M. Yasuda,et al.  Selection of Mycoplasma genitalium strains harbouring macrolide resistance-associated 23S rRNA mutations by treatment with a single 1 g dose of azithromycin , 2011, Sexually Transmitted Infections.

[20]  H. Moi,et al.  Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study , 2008, International journal of STD & AIDS.

[21]  J. Jensen,et al.  Antibiotic treatment of symptomatic Mycoplasma genitalium infection in Scandinavia: a controlled clinical trial , 2007, Sexually Transmitted Infections.

[22]  G. Amsden,et al.  Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. , 2001, The Journal of antimicrobial chemotherapy.

[23]  M. Kinzig,et al.  The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. , 1993, The Journal of antimicrobial chemotherapy.

[24]  G. Foulds,et al.  Selection of dose regimens of azithromycin . , 1993, The Journal of antimicrobial chemotherapy.